Thanks for that pickup Vintage.
I just went back and checked because I had thought that efficacy of diagnosing stroke location and type was a part of the stage 2 endpoints although I got that wrong.... my mistake.
Given that clarification I agree with you that a commercial distribution partnership will likely follow the validation phase.
EMvision Research Notes, page-2324
-
- There are more pages in this discussion • 238 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add EMV (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
$2.02 |
Change
0.010(0.50%) |
Mkt cap ! $172.5M | |||
| Open | High | Low | Value | Volume |
| $2.02 | $2.02 | $2.00 | $28.54K | 14.16K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 1 | 3000 | $1.95 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $2.02 | 13617 | 2 |
View Market Depth
| Last trade - 16.10pm 21/06/2024 (20 minute delay) ? |
| EMV (ASX) Chart |